▟ Vinebot intrinsic value, daily

← back

AFL Aflac

insurance · valued with opus medium conviction · deep-dived 2026-11-02

HOLD
Intrinsic value$83.55
Price (at call)$123.89
Margin of safety -32.6%
vs market (rating basis) -16.3%

Elite, durable Japan franchise, but buyback-limited book growth and yen drag leave shares priced above fair value.

The story

Aflac runs a dominant, high-margin supplemental health and cancer insurance franchise in Japan and the US. Underwriting is consistently profitable and the balance sheet is conservatively reserved. Trailing ROE of 16.5% is inflated: rising JGB yields have pushed down AOCI, which shrinks the reported book. Revenue keeps slipping (about 3% a year over five years) because of yen weakness and a mature Japan block. Heavy buybacks of roughly $3B a year return most earnings rather than compounding book, and through-the-cycle returns should sit closer to the low-to-mid teens.

I moved ROE up 50bp from 13.5% to 14% because the higher returns have held for several quarters. I did not extrapolate the 16.5% trailing figure, because the AOCI-depressed denominator and realized gains flatter it. Book growth stays low because buybacks and dividends take out most of earnings and the yen translation drags on reported equity. Beta stays at the 0.9 industry anchor, and failure risk is minimal given the reserving discipline and capital buffers.

Value drivers

Return on equity (normalized)14.0%
Book-value growth (Y1)3.0%
Terminal book growth2.5%
Beta0.90
Failure probability1.0%
Cost of equity9.0%

Valuation bridge

PV of excess returns7.77B
PV of terminal excess5.05B
Equity value41.89B
÷ shares → per share$83.55

Projected excess returns on equity

YrBook equityROEExcess returnPV
129.49B 14.0%1.48B 1.36B
230.37B 13.7%1.42B 1.20B
331.27B 13.3%1.36B 1.05B
432.17B 13.0%1.29B 915.57M
533.08B 12.7%1.22B 791.69M
634.00B 12.3%1.14B 678.50M
734.93B 12.0%1.05B 575.33M
835.86B 11.7%957.94M 481.50M
936.80B 11.3%859.44M 396.40M
1037.74B 11.0%754.73M 319.42M

Key risks

  • Further yen depreciation shrinks reported USD earnings and book
  • Japan third-sector sales stagnate and the policyholder base ages, which erodes revenue
  • Credit losses in the US corporate and private-credit investment portfolio, or JGB rate volatility hitting ESR and capital

Catalysts

  • Higher Japanese reinvestment yields lift net investment income over time
  • Product launches such as new cancer and medical riders reviving Japan sales momentum

History

DatePriceIntrinsicMoSRating
2026-11-02$123.89 $83.55 -32.6% HOLD
2026-09-30$113.66 $80.71 -29.0% HOLD
2026-08-28$116.58 $82.63 -29.1% HOLD
2026-07-28$126.56 $81.56 -35.6% HOLD
2026-06-24$118.79 $82.50 -30.6% HOLD
2026-06-22$116.55 $88.72 -23.9% HOLD